Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
86 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 1, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively. Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Liver Failure (Hepatic Insufficiency) - Overview Liver Failure (Hepatic Insufficiency) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development Alfact Innovation BioLineRx Ltd Cell2B Advanced Therapeutics SA Conatus Pharmaceuticals Inc Immune Pharmaceuticals Inc Mina Therapeutics Ltd Mylan NV Ocera Therapeutics Inc PledPharma AB Promethera Biosciences SA Silence Therapeutics Plc Unicyte AG Ventria Bioscience Vital Therapies Inc Liver Failure (Hepatic Insufficiency) - Drug Profiles ALF-5755 - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense RNAi Oligonucleotide to Inhibit FAS for Liver Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Antisense RNAi Oligonucleotides to Inhibit MKK4 for Liver Failure - Drug Profile Product Description Mechanism Of Action R&D Progress BL-1220 - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Acute Liver Failure and Alcoholic Hepatitis - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Liver Failure - Drug Profile Product Description Mechanism Of Action R&D Progress emricasan - Drug Profile Product Description Mechanism Of Action R&D Progress F-573 - Drug Profile Product Description Mechanism Of Action R&D Progress HepaStem - Drug Profile Product Description Mechanism Of Action R&D Progress ImmuneSafe - Drug Profile Product Description Mechanism Of Action R&D Progress MTL-CEBPA - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotide for Liver Failure - Drug Profile Product Description Mechanism Of Action R&D Progress ornithine phenylacetate - Drug Profile Product Description Mechanism Of Action R&D Progress PP-100 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile Product Description Mechanism Of Action R&D Progress silibinin - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile Product Description Mechanism Of Action R&D Progress VEN-100 - Drug Profile Product Description Mechanism Of Action R&D Progress XEN-103 - Drug Profile Product Description Mechanism Of Action R&D Progress Liver Failure (Hepatic Insufficiency) - Dormant Projects Liver Failure (Hepatic Insufficiency) - Discontinued Products Liver Failure (Hepatic Insufficiency) - Product Development Milestones Featured News & Press Releases Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016 Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure Nov 19, 2015: Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting Apr 11, 2013: Gene inhibition helps to improve liver regeneration Apr 02, 2013: ALF-5755 phase II completion Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury Sep 04, 2012: Ventria Bioscience And University Of Colorado Receive NIH Grant To Study Treatment Of Acetaminophen Overdose-Induced Liver Failure Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure May 06, 2011: ALF-5755 phase II extends to germany Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Alfact Innovation, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Conatus Pharmaceuticals Inc, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Silence Therapeutics Plc, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Ventria Bioscience, H1 2017 Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H1 2017 Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2017 Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
